免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
黑色素瘤免疫治疗的演变格局
英文原题：Evolving Landscape of Immunotherapy in Melanoma.
查看英文原题
Evolving Landscape of Immunotherapy in Melanoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫疗法彻底改变了皮肤黑色素瘤的治疗格局。免疫检查点抑制剂于2011年首次获批用于黑色素瘤，现已成为黑色素瘤治疗的主要手段。近年来，TIL（肿瘤浸润淋巴细胞）疗法为我们的黑色素瘤免疫治疗武器库增添了令人振奋的新选择。免疫疗法已将高危局限性黑色素瘤患者的无复发生存期以及转移性疾病患者的总生存期从历史上仅数月的预后改善至数年之久。尽管取得了这些进展，并非每位患者都能从中获益，这凸显了持续创新和优化黑色素瘤治疗的迫切需求。本综述概述了我们管理局限性和转移性黑色素瘤的方法，重点介绍了支持我们决策的关键数据。我们还重点介绍了有望在未来数年塑造黑色素瘤治疗格局的正在进行的临床试验。
展开英文摘要原文
Cutaneous melanoma management has been revolutionized by immunotherapy. Immune checkpoint inhibitors, first approved for melanoma in 2011, have become a mainstay in melanoma management. More recently, tumor infiltrating lymphocyte therapy has represented an exciting addition to our immunotherapeutic armamentarium against melanoma.
Immunotherapy has improved relapse-free survival in patients with high-risk localized melanoma and overall survival in patients with metastatic disease to the order of years from historic prognoses of just months. Despite these advancements, not every patient benefits, highlighting the need for continued innovation and refinement of melanoma treatment. This review provides an overview of our approach to managing localized and metastatic melanoma, highlighting key data supporting our decision making.
We also highlight ongoing trials poised to shape the future of melanoma care in the coming years.
论文信息
- 作者
- Darwin AH、Dickerson JC、Funchain P
- 第一作者单位
- Department of Medicine, Stanford University School of Medicine, Stanford, CA.United States
- 通讯作者单位
- Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.United States
- 期刊
- JCO oncology practice2026 Jun 25
- 原文标识
- PubMed 42348813 · DOI 10.1200/OP-25-01301